HMGB1 and cancer: One study identified N6F11 as a selective ferroptosis inducer that degrades GPX4 specifically in cancer cells without affecting immune cells, thereby triggering ferroptosis in cancer cells and initiating HMGB1-dependent antitumor immunity mediated by CD8+ T cells.